We read with great interest the manuscript authored by Stryckers et al. [1] that presents a unique case report highlighting drug-induced focal segmental glomerulosclerosis (FSGS) in a patient undergoing interleukin-23 (IL-23) inhibitor treatment with guselkumab. The gene discussed is IL37; the disease is focal segmental glomerulosclerosis.